FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808094802> ?p ?o ?g. }

• W2808094802 abstract "Background Patients with rheumatoid arthritis (RA) often receive methotrexate (MTX) in combination with biologics; however, MTX may be discontinued due to intolerance or to reduce the medication burden once disease control is achieved. Whereas previous studies have established the efficacy of tocilizumab (TCZ) initiated as monotherapy (MONO) for the treatment of RA, 1,2 patient-reported outcomes (PROs) after MTX withdrawal in patients achieving good clinical response to TCZ +MTX have not been evaluated. PROs are important measures when determining response to therapy in patients with RA with respect to health-related quality of life (HRQOL). 3,4 Objectives This study evaluated PROs between patients with RA who achieved low disease activity with TCZ +MTX and then continued or discontinued MTX in the COMP-ACT trial (NCT01855789). Methods US patients with RA who were inadequate responders to MTX were enrolled; initial combination therapy included MTX (≥15 mg/week orally) plus TCZ 162 mg subcutaneous either weekly (qw) or every 2 weeks (q2w). Patients who achieved DAS28-ESR≤3.2 at Week 24 were randomised 1:1 to receive TCZ-MONO or continue TCZ +MTX until week 52 (double-blind). Changes in PRO scores were measured between Week 24 and Weeks 40 and 52, and included patient global assessment of disease activity (PtGA; visual analogue score [VAS], 0–100 mm), pain (VAS), Health Assessment Questionnaire Disability Index (HAQ-DI, 0–3) and Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue. Results Of the 296 randomised patients (TCZ +MTX, n=148; TCZ-MONO, n=148), 74.8% were women, mean age was 55.5 years, mean RA duration was 6.8 years and mean DAS28-ESR was 6.3 at baseline. At Week 24 (randomization), PRO scores were similar between the randomised treatment groups. The mean changes in PtGA, pain, HAQ-DI and FACIT-fatigue scores from Week 24 to Weeks 40 were similar between the TCZ +MTX and TCZ-MONO groups (table 1). The proportion of patients with HAQ-DI Conclusions Patients receiving TCZ who discontinue MTX appear to have similar PROs across multiple measures compared with patients continuing TCZ +MTX. Differences observed in clinical parameters between TCZ-MONO and TCZ +MTX did not appear to achieve a threshold that would be considered clinically meaningful. Similarities in PROs on both treatments were consistent with the clinical efficacy measures previously reported from COMP-ACT. References [1] Jones G, et al. J Rheumatol2017;44(2):142–6. [2] Dougados M, et al. Ann Rheum Dis. 2013;72(1):43–50. [3] Deshpande PR, et al. Perspect Clin Res. 2011;2(4):137–44. [4] Her M, Kavanaugh A. Curr Opin Rheumatol. 2012;24(3):327–34. Acknowledgements This study was funded by Genentech, Inc. Disclosure of Interest J. Kremer Shareholder of: Corrona, LLC, Consultant for: Abbvie, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, GlaxoSmithKline, Pfizer, Regeneron and Sanofi, W. Rigby Consultant for: Roche/Genentech, N. Singer Grant/research support from: Merck/EMD Serono (in kind lab resources) and unrestricted educational grants from several companies to MetroHealth for 2016 Cleveland Society of Rheumatology, C. Birchwood Employee of: Genentech, Inc., D. Gill Employee of: Genentech, Inc., W. Reiss Employee of: Genentech, Inc., J. Best Employee of: Genentech, Inc., J. Pei Employee of: Genentech, Inc., M. Michalska Employee of: Genentech, Inc." @default.
• W2808094802 created "2018-06-21" @default.
• W2808094802 creator A5000643400 @default.
• W2808094802 creator A5006738078 @default.
• W2808094802 creator A5014147030 @default.
• W2808094802 creator A5018367518 @default.
• W2808094802 creator A5020173623 @default.
• W2808094802 creator A5027054405 @default.
• W2808094802 creator A5030738776 @default.
• W2808094802 creator A5041844509 @default.
• W2808094802 creator A5071962255 @default.
• W2808094802 date "2018-06-01" @default.
• W2808094802 modified "2023-09-27" @default.
• W2808094802 title "AB0448 Patient-reported outcomes following discontinuation of methotrexate in patients with rheumatoid arthritis treated with subcutaneous tocilizumab: results from a randomised controlled trial" @default.
• W2808094802 doi "https://doi.org/10.1136/annrheumdis-2018-eular.1838" @default.
• W2808094802 hasPublicationYear "2018" @default.
• W2808094802 type Work @default.
• W2808094802 sameAs 2808094802 @default.
• W2808094802 citedByCount "1" @default.
• W2808094802 countsByYear W28080948022017 @default.
• W2808094802 crossrefType "proceedings-article" @default.
• W2808094802 hasAuthorship W2808094802A5000643400 @default.
• W2808094802 hasAuthorship W2808094802A5006738078 @default.
• W2808094802 hasAuthorship W2808094802A5014147030 @default.
• W2808094802 hasAuthorship W2808094802A5018367518 @default.
• W2808094802 hasAuthorship W2808094802A5020173623 @default.
• W2808094802 hasAuthorship W2808094802A5027054405 @default.
• W2808094802 hasAuthorship W2808094802A5030738776 @default.
• W2808094802 hasAuthorship W2808094802A5041844509 @default.
• W2808094802 hasAuthorship W2808094802A5071962255 @default.
• W2808094802 hasBestOaLocation W28080948021 @default.
• W2808094802 hasConcept C126322002 @default.
• W2808094802 hasConcept C14184104 @default.
• W2808094802 hasConcept C159110408 @default.
• W2808094802 hasConcept C168563851 @default.
• W2808094802 hasConcept C1862650 @default.
• W2808094802 hasConcept C197934379 @default.
• W2808094802 hasConcept C2777077863 @default.
• W2808094802 hasConcept C2777178219 @default.
• W2808094802 hasConcept C2777575956 @default.
• W2808094802 hasConcept C2778715236 @default.
• W2808094802 hasConcept C2779951463 @default.
• W2808094802 hasConcept C2781059491 @default.
• W2808094802 hasConcept C535046627 @default.
• W2808094802 hasConcept C71924100 @default.
• W2808094802 hasConceptScore W2808094802C126322002 @default.
• W2808094802 hasConceptScore W2808094802C14184104 @default.
• W2808094802 hasConceptScore W2808094802C159110408 @default.
• W2808094802 hasConceptScore W2808094802C168563851 @default.
• W2808094802 hasConceptScore W2808094802C1862650 @default.
• W2808094802 hasConceptScore W2808094802C197934379 @default.
• W2808094802 hasConceptScore W2808094802C2777077863 @default.
• W2808094802 hasConceptScore W2808094802C2777178219 @default.
• W2808094802 hasConceptScore W2808094802C2777575956 @default.
• W2808094802 hasConceptScore W2808094802C2778715236 @default.
• W2808094802 hasConceptScore W2808094802C2779951463 @default.
• W2808094802 hasConceptScore W2808094802C2781059491 @default.
• W2808094802 hasConceptScore W2808094802C535046627 @default.
• W2808094802 hasConceptScore W2808094802C71924100 @default.
• W2808094802 hasLocation W28080948021 @default.
• W2808094802 hasOpenAccess W2808094802 @default.
• W2808094802 hasPrimaryLocation W28080948021 @default.
• W2808094802 isParatext "false" @default.
• W2808094802 isRetracted "false" @default.
• W2808094802 magId "2808094802" @default.
• W2808094802 workType "article" @default.